ProNova SC360 Selected for New Proton Center in Biopolis Singapore

CONTACT:  Bill Hansen   |  (865) 360-1015   |   .(JavaScript must be enabled to view this email address)

Knoxville, Tenn., USA (September 14, 2014) - - Singapore Institute of Advanced Medicine Holdings Pte Ltd (SAM) and ProNova announced today that ProNova has been selected by SAM as its partner to establish the first proton therapy facility in Singapore.  The SC360 proton therapy system will be an essential element of a new outpatient cancer center located on the Singapore Biopolis campus, an international research and development center for biomedical sciences.

ProNova will equip the new center with two superconducting gantry proton treatment rooms including an additional room dedicated to research.  Each treatment room will include Fast Scanning IMPT technology with integrated 3D imaging.  This unique solution merges leading edge pencil beam delivery with innovative imaging capability to aid physicians and therapists in minimizing collateral damage to healthy tissue and maximizing dose to the tumor.

“We believe proton therapy is a significant step forward in our treatment of cancer and ProNova has proven to be the best partner with next generation technology,” said Dr. Djeng Shih Kien, SAM’s founder and chairman.

“We are pleased to partner with SAM in bringing the first proton center to Singapore,” said Dr. Terry Douglass, Chairman and CEO of ProNova Solutions. “We look forward to providing our unique total solutions offerings and sharing our proton therapy knowledge and clinical experience with SAM’s staff. We believe that the new developments in proton therapy and other cancer treatment technologies accomplished at the SAM ProNova Biopolis Cancer Center will be a major step in redefining the future of cancer treatment.”

The new $100 million cancer and proton center will be located on the Biopolis Campus in Singapore.  Biopolis is the hallmark of Singapore's R&D success. Today, leading pharmaceutical companies such as Abbott, GlaxoSmithKline, Lilly, Novartis, Schering-Plough and Takeda have established their R&D base in the Biopolis. There are now more than 2,000 scientists from around the world carrying out research on this campus.

The Singapore Biopolis is strategically located next to the Kent Ridge Campus, where a public hospital and medical school are located, thereby facilitating translational and clinical research. The specialized research institutes at Kent Ridge include the Cancer Science Institute of Singapore. Leading companies such as AstraZeneca and Bayer Schering Pharma are partnering research units in the National University Health System at Kent Ridge for translational cancer research.

About Proton Therapy

Proton therapy is an advanced form of radiation therapy that uses a single beam of high-energy protons to treat various forms of cancer. Just as with conventional radiation therapy, proton treats tumors by directing radiation into the tumor site where doses of radiation destroy cancerous cells. However, unlike conventional radiation therapy, in which x-ray beams deposit their energy into the healthy tissue before and after the tumor site, physicians can control the timing and dosage of energy from protons, which allows the maximum energy deposited directly into the tumor, reducing damage to nearby healthy tissue and thus limiting negative side effects.

About SAM

SAM believes in bringing the latest technologies in medical advances to this part of the world. The company has been collaborating with leading companies in the healthcare industry to provide comprehensive diagnostic services in imaging and laboratory, as well as advance methodologies in treatment.

About ProNova Solutions, LLC

ProNova is committed to making proton therapy accessible to a greater number of patients and physicians worldwide. Founded by the leaders of CTI Molecular Imaging, ProNova’s team brought positron emission tomography (PET) technology out of the laboratory and made it a clinical reality for millions of cancer patients. Our team's early work revolutionized cancer diagnostics and helped to develop an industry with over 350 cyclotrons, more than 3,000 PET & PET/CT systems and 160 PET radiopharmaceutical distribution centers installed around the world today.  The same team will redefine cancer treatment once again with the introduction of the SC360 proton therapy system.